Introduction:
The global market for SGLT-2 inhibitor drugs, such as Jardiance and Farxiga, is experiencing significant growth as these medications continue to show promising results in managing diabetes and reducing the risk of cardiovascular events. According to recent market research, the global SGLT-2 inhibitor market is projected to reach $8.3 billion by 2026, with a compound annual growth rate of 9.5%.
Top 10 Global SGLT-2 Inhibitor Drug Brands:
1. Jardiance (Eli Lilly and Boehringer Ingelheim)
Jardiance is one of the leading SGLT-2 inhibitor drugs on the market, with a global market share of 32%. It has been shown to significantly reduce the risk of heart failure and cardiovascular death in patients with type 2 diabetes.
2. Farxiga (AstraZeneca)
Farxiga is another top SGLT-2 inhibitor drug brand, with a market share of 25%. Studies have demonstrated its effectiveness in reducing the risk of major adverse cardiovascular events in diabetic patients.
3. Invokana (Johnson & Johnson)
Invokana is a well-known SGLT-2 inhibitor drug brand with a market share of 18%. It has been shown to improve cardiovascular outcomes and reduce the risk of kidney disease in diabetic patients.
4. Steglatro (Merck)
Steglatro is a newer SGLT-2 inhibitor drug brand with a market share of 10%. It has gained popularity for its ability to lower blood sugar levels and reduce the risk of cardiovascular events in patients with diabetes.
5. Steglujan (Merck)
Steglujan is a combination SGLT-2 inhibitor drug brand developed by Merck, with a market share of 6%. It has been shown to improve glycemic control and reduce the risk of cardiovascular events in diabetic patients.
6. Forxiga (AstraZeneca)
Forxiga is a widely used SGLT-2 inhibitor drug brand with a market share of 5%. It has been shown to reduce the risk of hospitalization for heart failure in patients with type 2 diabetes.
7. Qtern (AstraZeneca)
Qtern is a combination SGLT-2 inhibitor drug brand developed by AstraZeneca, with a market share of 3%. It has been shown to improve glycemic control and reduce the risk of cardiovascular events in diabetic patients.
8. Xigduo XR (AstraZeneca)
Xigduo XR is another combination SGLT-2 inhibitor drug brand developed by AstraZeneca, with a market share of 2%. It has been shown to reduce blood sugar levels and improve cardiovascular outcomes in diabetic patients.
9. Synjardy (Boehringer Ingelheim and Eli Lilly)
Synjardy is a combination SGLT-2 inhibitor drug brand developed by Boehringer Ingelheim and Eli Lilly, with a market share of 2%. It has been shown to reduce the risk of cardiovascular events and kidney disease in patients with type 2 diabetes.
10. Segluromet (Merck)
Segluromet is a combination SGLT-2 inhibitor drug brand developed by Merck, with a market share of 1%. It has been shown to improve glycemic control and reduce the risk of cardiovascular events in diabetic patients.
Insights:
The global market for SGLT-2 inhibitor drugs is expected to continue growing at a steady pace, driven by the increasing prevalence of diabetes and the growing awareness of the benefits of these medications in reducing the risk of cardiovascular events. With ongoing research and development efforts, new and improved SGLT-2 inhibitor drugs are likely to enter the market, further expanding treatment options for diabetic patients. By 2026, the global market for SGLT-2 inhibitor drugs is projected to exceed $8 billion, with a significant portion of sales coming from emerging markets in Asia and Latin America.
Related Analysis: View Previous Industry Report
